Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, I think this will be the talk of 2018 $$$ I've been holding since Feb. and added more in March. What's another few months !! Not selling anything. Summer always fly by then September will be here in no time. Then Italy in October for 3 weeks then come Christmas and BOOM 2018 $$$ with Health Canada approval and FDA approval. $$$ Millionaire by next Summer. Lol !!!
Does anyone knows why we are not trading today?
We got update. Go TBP/TBPMF $$$
Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals
05 July, 2017
OTTAWA, ONTARIO--(Marketwired - July 5, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug. Tetra has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017. According to this report, Tetra is the only company developing dried marijuana as a drug.
One in five Canadians will live with pain in their lifetime and one in two will be affected by cancer. Canadian courts have ruled in favor of patients wanting access to marijuana for relief. In response to these decisions, the Canadian government has implemented the Access to Cannabis for Medical Purposes Regulations (ACMPR) to help bring marijuana to patients. Canada's Prime Minister has been very favorable in bringing marijuana to patients but it will be up to corporations to step in and adhere to the Canadian Food and Drug regulations to bring marijuana medications to patients. Tetra is a world leader in the drug development field of cannabis-based medications and is paving the road to become the first company to commercialize a dried marijuana product as a drug in North America.
"Canadian's are entitled to access to marijuana to treat their pain or its co-morbidities. It is not a question of social standing or a judgement if the act of 'smoking' is acceptable for patients. It is a fundamental right to have access to a botanical drug that can effectively allow patients to have a better quality of life," commented Dr. Guy Chamberland, CSO of Tetra Bio-Pharma. "There is sufficient evidence suggesting that smoking marijuana is an adequate medication to help relieve pain and improve a patient's well-being. Both of these are important aspects to offering effective therapies to patients. The challenge has been addressing quality and safety issues to meet the standards of a drug."
Over the years our society has inherited an image that 'smoking' or 'vaporizing' is not associated with a healthy approach to health care. According to the expert committee on the Health Effects of Marijuana (National Academies Press, 2017), 'smoking cannabis does not increase the risk for certain cancers (i.e., lung, head and neck)'. In addition, cancer patients typically consume an amount of dried marijuana per day, in dry weight, that is less than 1 tobacco cigarette, without the paper, per day. The significantly reduced amount of smoke per day is one of the explanations supporting that smoking marijuana does not increase the risk for these cancers. That said, these are effective routes of delivering a complex botanical medication. "Society has to focus on caring for all patients living with pain not just those that want a different dosage form," commented Dr. Chamberland. He added, "In fact our challenge is to characterize the safety and efficacy of this therapy, ensure lot-to-lot quality, provide adequate risk information to health professionals, demonstrate the safety and efficacy so that physicians can adequately assess the potential efficacy and safety for their patient, and actively pursue more tolerable dosage forms to offer these innovative cannabis therapies to patients. In the end, a patient's desire to smoke marijuana for relief has to be defended by Canadian courts and politicians. We live in a democratic society and we have to care for everyone."
"Tetra undertook the development of PPP001 as a first prescription marijuana drug. The company is preparing its phase 3 trial in cancer patients and will assess the safety and efficacy using both the titanium pipe and vaporizer delivery systems. From Day 1, Tetra was dedicated to characterizing the safety and tolerability of consuming medical marijuana by smoking. Tetra also adopted the firm position of working transparently with regulators because the corporation believed it is important to bring marijuana, as traditionally used, to patients. Tetra will continue to work with provincial and federal governments, including physician and pharmacist professional corporations, to help address issues associated with the development and commercialization of a first prescription medical marijuana drug."
"Tetra already works closely with Health Canada through the regulatory processes in place for the development of drugs and controlled substances," commented Dr. Chamberland. He added that, "Tetra was working closely with the province of New Brunswick whom from Day 1 was very active in preparing for the eventual legalization of marijuana in Canada. Tetra is working with physician and pharmacist professional associations/corporations and will be working closely with these health professionals as the company prepares for its Phase 3 trial and the eventual commercialization of the first dried marijuana drug."
"Tetra has performed safety, pharmacokinetic and cognitive function studies in healthy volunteers. The corporation has characterized the safety of consuming marijuana and understands what the potential risks are to consumers and patients. This information will be made available by Tetra to Health Canada and to other government departments on request. We believe that this safety data provides a clear and accurate picture of what happens to people that smoke marijuana recreationally," commented Dr. Chamberland. "We believe it is our responsibility to provide this information to regulators to help pave the road for the Trudeau government's legalization."
In addition, Tetra will use its clinical knowledge from its Phase 1 and Safety clinical studies to implement effective and secure patient care programs. This includes working with independent professional organizations to transfer its clinical risk information and ensure that these groups provide continued medical education to their health professionals. Dr. Chamberland commented, "Launching the first dried marijuana drug in Canada brings a responsibility of ensuring that all safety risks are communicated to health professionals to ensure the well-being of consumers. No body wants another fentanyl-type crisis; all we want is for patients to obtain relief and an improved quality of life when consuming marijuana that is of the same quality as any other prescription medication."
"Tetra will be actively pursuing the development and commercialization of PPP001 to remain a world leader in the field of cannabis medicine," commented Andre Rancourt, CEO of Tetra Bio-Pharma. "We are dedicated to working with distributors and pharmaceutical companies interested in bringing medical marijuana as a prescription drug around the world. We are focusing on bringing to patients what the Supreme Court of Canada ruled was their right: access to marijuana."
About Tetra Bio-Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
Not sure why but it's been like this with many stock this week. Lost almost half of my money but not worried. We will fly soon.
This is real enough for me!! One of the video has a FastFrate trailer in the back ground which is a Canadian company and !! the mini van has a plate of Ontario !! I can't read the top of the license plate but sure looks like an Ontario license plate!!
Go PSRU $$$
ERFB, agreed this will move!!!
I'm in .0235. Didn't move much Lol !! Hopping we have more buyers soon.
Ok, I'm back in this one .0259. Give us some news update something !!! This is ready to fly !!
Love the fact they are supporting my province New-Brunswick. Go TBP !!! Awesome news !!
Speculation of GOLD people buy in. We strike GOLD and people sell. LOL !!!!
We are live keep your shares. This is not the same company as last week. Lets ride this up to .05 !!
I got out late yesterday to get in the cat game late yesterday. Lol but I sill think their might be some potential here next week. Chart still looks good.
Any updates or news would be good at this time. Thanks.
Awesome news !!
Agreed!! bid was always in 3s for the last few days we got it at .043. Time to move up !!!
Remember what you are in here for!!! Summary:
Tetra Bio-Pharma: The Canadian Pioneer in Cannabis-Based Pharma for Pain Relief in Cancer Patients
May 16, 2017 / TheNewswire / MONTREAL, QUEBEC -- Momentum PR client, Tetra Bio-Pharma is listed on the Canadian Securities Exchange under the symbol TBP as well as on the OTCQB in the US under the symbol GRPOF
Momentum PR is pleased to have produced an informative and comprehensive report on Tetra Bio-Pharma available on the Momentum PR LinkedIn page.
Tetra Bio-Pharma Highlights:
- Canadian-based pioneer, innovator and first to market in cannabis-based pharmaceuticals
- Global medical marijuana market is estimated to reach US$55.8 billion by 2025
- Tetra Bio-Pharma is the first and only bio-pharma company in North-America focused on cannabinoid (CBD) clinical stage pain relief products
- Tetra is the only bio-pharma company currently running a double-blind Phase 1 study with organically-grown cannabis
- Positive outcome from trials will result in for North-American Drug Identification Numbers (DIN), thus qualifying prescriptions for insurance coverage.
- Strategic partnership with Aphria Inc. announced in November 2016 and solidified in April 2017
Tetra Bio-Pharma is a Canadian-based pioneer, innovator and first market mover in developing cannabis-based pharmaceuticals. These are used for the treatment of cancer-related pain and the resultant nausea, as well as anorexia and Post Traumatic Stress Disorder (PTSD).
The global medical marijuana market is estimated to reach US$55.8 billion by 2025, according to Grand View Research. Health Canada has stated that they expected a mature medical marijuana market worth C$1.3 billion by 2024 in Canada alone.
Tetra Bio-Pharma is the first and only bio-pharmaceutical company in North-America that is focused on cannabinoid (CBD) clinical stage pain relief products. The Company believes that if all goes well, its flagship drug, PPP001, designed to treat the chronic pain associated with many cancers, will be on the market in 2019. The Canadian Cancer Society is estimating a 35% growth rate in cancer cases in Quebec, and 40% nationally by 2030. They also advocate for more spending on research on innovative drugs and end-of-life treatment.
Tetra Bio-Pharma is accelerating the acceptance of cannabis-based medical treatments. It is the only bio-pharmaceutical company currently running a double-blind Phase 1 study. It aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single and multi-daily ascending doses of cannabis by smoking in healthy volunteers.
Pending a positive outcome, cannabis-based drugs designed to treat cancer pain and nausea from chemotherapy, PTSD and a number of other ailments will qualify for North-American Drug Identification Numbers (DIN). This means that prescriptions would be eligible for insurance coverage.
In addition to developing proprietary products and intellectual property, Tetra Bio-Pharma signed a supply agreement with ACMPR licensed producer Aphria Inc. on November 3, 2016. The Tetra-Aphria partnership was further solidified on April 19, 2017 when plans were announced for the joint distribution of dried medical cannabis for Quebec and the Atlantic Provinces.
The Momentum PR informative and comprehensive report on Tetra Bio-Pharma is available on the Momentum PR LinkedIn page.
If you would like more information on Tetra Bio-Pharma listed on the Canadian Securities Exchange under the symbol TBP with a market cap of C$ 70 million, or would like to arrange an interview with management please contact:
Momentum PR
Juliette Benard, Director Media Relations
+1.450.332.6939
I think will bounce back up hard by the end of the day. Can you imagine not having any shares for tomorrow morning. If the news is great you want be buying at these level for sure.
I think MM want to see who will sell their shares for tomorrow. I'm not giving them one share !!
TPB / TBPMF NOW!!! discount want last long .89 easy to 1.00 expecting major news tomorrow.
Agree, the chart looks great. The earth is shaking, just a matter of time she explodes !!
TBP / TBPMF are expecting great news on trial this week. This will pop !!
RLBD - Check it out, ready to breakout !!
RLBD - Check it out, ready to breakout !!
Can't wait to see some news about the trial. Suppose to be this week !!!
Let see this thing move up today !!
RLBD - at the bottom, still a few left a .04 want last long !!!
I'm in!!! .04 !!! Lets get moving!!
Any one think will have a power hour? That would be fun. It's under value and not a lot of people are looking at this guy but I think it could run 40% easily.
Awesome !!!
TBP (CAD) or TBPMF (US) is on the move. This will be big !!
They added more news yesterday plus this last week!!
May 16, 2017 / TheNewswire / MONTREAL, QUEBEC -- Momentum PR client, Tetra Bio-Pharma is listed on the Canadian Securities Exchange under the symbol TBP as well as on the OTCQB in the US under the symbol GRPOF
Momentum PR is pleased to have produced an informative and comprehensive report on Tetra Bio-Pharma available on the Momentum PR LinkedIn page.
Tetra Bio-Pharma Highlights:
- Canadian-based pioneer, innovator and first to market in cannabis-based pharmaceuticals
- Global medical marijuana market is estimated to reach US$55.8 billion by 2025
- Tetra Bio-Pharma is the first and only bio-pharma company in North-America focused on cannabinoid (CBD) clinical stage pain relief products
- Tetra is the only bio-pharma company currently running a double-blind Phase 1 study with organically-grown cannabis
- Positive outcome from trials will result in for North-American Drug Identification Numbers (DIN), thus qualifying prescriptions for insurance coverage.
- Strategic partnership with Aphria Inc. announced in November 2016 and solidified in April 2017
Tetra Bio-Pharma is a Canadian-based pioneer, innovator and first market mover in developing cannabis-based pharmaceuticals. These are used for the treatment of cancer-related pain and the resultant nausea, as well as anorexia and Post Traumatic Stress Disorder (PTSD).
The global medical marijuana market is estimated to reach US$55.8 billion by 2025, according to Grand View Research. Health Canada has stated that they expected a mature medical marijuana market worth C$1.3 billion by 2024 in Canada alone.
Tetra Bio-Pharma is the first and only bio-pharmaceutical company in North-America that is focused on cannabinoid (CBD) clinical stage pain relief products. The Company believes that if all goes well, its flagship drug, PPP001, designed to treat the chronic pain associated with many cancers, will be on the market in 2019. The Canadian Cancer Society is estimating a 35% growth rate in cancer cases in Quebec, and 40% nationally by 2030. They also advocate for more spending on research on innovative drugs and end-of-life treatment.
Tetra Bio-Pharma is accelerating the acceptance of cannabis-based medical treatments. It is the only bio-pharmaceutical company currently running a double-blind Phase 1 study. It aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single and multi-daily ascending doses of cannabis by smoking in healthy volunteers.
Pending a positive outcome, cannabis-based drugs designed to treat cancer pain and nausea from chemotherapy, PTSD and a number of other ailments will qualify for North-American Drug Identification Numbers (DIN). This means that prescriptions would be eligible for insurance coverage.
In addition to developing proprietary products and intellectual property, Tetra Bio-Pharma signed a supply agreement with ACMPR licensed producer Aphria Inc. on November 3, 2016. The Tetra-Aphria partnership was further solidified on April 19, 2017 when plans were announced for the joint distribution of dried medical cannabis for Quebec and the Atlantic Provinces.
The Momentum PR informative and comprehensive report on Tetra Bio-Pharma is available on the Momentum PR LinkedIn page.
If you would like more information on Tetra Bio-Pharma listed on the Canadian Securities Exchange under the symbol TBP with a market cap of C$ 70 million, or would like to arrange an interview with management please contact:
Momentum PR
Juliette Benard, Director Media Relations
+1.450.332.6939
media@momemtumpr.com
info@momentumpr.com
http://momentumpr.com/
- See more at: https://www.thenewswire.com/archives?id=LaPFQRq7#sthash.lcESs28c.dpuf
Finally the beast is starting to wake up!!! Congrads everyone that's been holding for all these months!! Here comes my early retirement in two years. After that I might just get a part time job with these guys in my hometown Moncton, NB to keep myself doing something. Contribute back to the company. LOL!!!
Come on we need to turn around or hopefully this is the bottom for a while until news comes out.
They were like an hour ago. I got 675304 at .0021 !!! Lets move up.
I'm into this one .0021 like an hour ago. Love the chart!! Time to bounce back up!!
Glad we are moving up!!! Go TBP / TBPMF !!
Fresh from the oven come and get them LOL!! This will move $$
On the chart the MACD is just crossing over today to be an up trend for a few days. Might as well buy now!! They want last long!!
This is what I'm hopping too !!! Let's go!!
I'm in .012 not much but 315$ is better than nothing !! LOL!!!
Awesome news. We support you TBP / GROPF $$$ in for the long road!